Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Mar 23;13(1):49.
doi: 10.1186/s13014-018-0991-4.

Partial Breast Irradiation With CyberKnife After Breast Conserving Surgery: A Pilot Study in Early Breast Cancer

Free PMC article
Clinical Trial

Partial Breast Irradiation With CyberKnife After Breast Conserving Surgery: A Pilot Study in Early Breast Cancer

Laura Lozza et al. Radiat Oncol. .
Free PMC article


Background: Local recurrences after breast conserving treatment are mainly close to the original tumor site, and as such shorter fractionation strategies focused on and nearest mammary gland, i.e. accelerated partial breast irradiation (APBI), have been developed. Stereotactic APBI has been attempted, although there is little experience using CyberKnife (CK) for early breast cancer.

Methods: This pilot study was designed to assess the feasibility of CK-APBI on 20 evaluable patients of 29 eligible, followed for 2 years. The primary endpoint was acute/sub-acute toxicity; secondary endpoints were late toxicity and the cosmetic result.

Results: Mean pathological tumor size was 10.5 mm (±4.3, range 3-18), 8 of these patients were classified as LumA-like, 11 as LumB-like, and 1 as LumB-HER2-enriched. Using CK-APBI with Iris, the treatment time was approximately 60 min (range~ 35 to ~ 120). All patients received 30 Gy in five fractions delivered to the PTV. The median number of beams was 180 (IQR 107-213; range:56-325) with a median PTV isodose prescription of 86.0% (IQR 85.0-88.5; range:82-94). The median PTV was 88.1 cm3 (IQR 63.8-108.6; range:32.3-238.8). The median breast V100 and V50 was 0.6 (IQR 0.1-1.5; range:0-13) and 18.6 (IQR 13.1-21.7; range:7.5-37), respectively. The median PTV minimum dose was 26.2 Gy (IQR 24.7-27.6; range 22.3-29.3). Mild side effects were recorded during the period of observation. Cosmetic evaluations were performed by three observers from the start of radiotherapy up to 2 years. Patients' evaluation progressively increase from 60% to 85% of excellent rating; this trend was similar to that of external observer.

Conclusions: These preliminary results showed the safe feasibility of CK-APBI in early breast cancer, with mild acute and late toxicity and very good cosmetic results.

Trial registration: The present study is registered at ( NCT02896322 ). Retrospectively egistered August 4, 2016.

Conflict of interest statement

Ethics approval and consent to participate

The study was evaluated and approved by the ethics commettee of both institute (Fondazione IRCCS Istituto Nazionale dei Tumori, protocol n° INT 109/12, and Fondazione IRCCS Istituto Neurologico Carlo Besta, protocol n° 111/2013). Furthermore the present study has been registered in n° NCT02896322). Written consent to participate to the present study was obtained from all patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Fig. 1
Fig. 1
Prevalence of side effects in the study population for different time points
Fig. 2
Fig. 2
Percentage of “Poor”, “Good” and “Excellent” evaluations given by physicians, patients and operators

Similar articles

See all similar articles

Cited by 2 articles


    1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241. doi: 10.1056/NEJMoa022152. - DOI - PubMed
    1. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized trial comparing brast conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–1232. doi: 10.1056/NEJMoa020989. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Darby S, McGale P, et al. Effect of radiotherapy after breast conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10.801 women in 17 randomised trials. Lancet. 2011;378:1707–1716. doi: 10.1016/S0140-6736(11)60993-8. - DOI - PMC - PubMed
    1. McCarthy EP, Ngo LH, Roetzheim RG, et al. Disparities in breast cancer treatment and survival for women with disabilities. Ann Intern Med. 2006;145:637–645. doi: 10.7326/0003-4819-145-9-200611070-00005. - DOI - PMC - PubMed
    1. Morrow M, White J, Moughan J, et al. Factors predicting the use of breast conserving therapy in stage I and II breast cancer. J Clin Oncol. 2001;19:2254–2262. doi: 10.1200/JCO.2001.19.8.2254. - DOI - PubMed

Publication types

Associated data